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PREAMBLE
These guidelines have been written to assist physicians and
other health care providers in the recognition, diagnosis, and
management of patients chronically infected with the hepati-
tis B virus (HBV). They are intended to suggest preferable
approaches to the clinical management of chronic hepatitis B.
The recommendations are flexible and are not intended as the
only acceptable approach to management and treatment. As
the appropriate course of treatment will vary in light of the
relevant facts and circumstances surrounding each individual
patient with chronic hepatitis B, guidelines are not intended
to define the applicable standard of medical care and may be
updated periodically as new information becomes available.
These guidelines were developed under the auspices of, and
approved by, the Practice Guidelines Committee of the Amer-
ican Association for the Study of Liver Diseases. They should
be taken as guidelines and not “standards of care.” Data used
to support the recommendations made were obtained by a
literature search of peer-reviewed articles concerning the nat-
ural history, diagnosis, and treatment of chronic hepatitis B.
In addition, the proceedings of a recent National Institutes of
Health workshop on the “Management of Hepatitis B” were
considered in the development of these guidelines.1 The
strength of each recommendation is categorized based on the
quality of evidence in the literature according to the rating
system indicated in Table 1.2
INTRODUCTION
An estimated 350 million persons worldwide are chroni-
cally infected with HBV.3 In the United States, there are an
estimated 1.25 million hepatitis B carriers, defined as persons
positive for hepatitis B surface antigen (HBsAg) for more than
6 months.4,5 Carriers of HBV are at increased risk of develop-
ing cirrhosis, hepatic decompensation, and hepatocellular
carcinoma (HCC).6 Although most carriers will not develop
hepatic complications from chronic hepatitis B, 15% to 40%
will develop serious sequelae during their lifetime.7 Recom-
mendations in these guidelines pertain to (1) evaluation of
patients with chronic HBV infection, (2) prevention of HBV
infection, (3) role of HCC surveillance, and (4) treatment of
chronic hepatitis B.
HEPATITIS B VIRUS
HBV belongs to the family of hepadnaviruses. The HBV
genome is a relaxed circular, partially double strandedDNAof
approximately 3,200 base pairs. There are 4 partially overlap-
ping open reading frames encoding the envelope (pre-S/S),
core (precore/core), polymerase, and X proteins.8,9 The pre-
S/S open reading frame encodes the large (L), middle (M), and
small (S) surface glycoproteins. The precore/core open read-
ing frame is translated into a precore polypeptide, which is
modified into a soluble protein, the hepatitis B e antigen
(HBeAg) and the nucleocapsid protein, hepatitis B core anti-
gen. Mutations in the core promoter and precore region have
been shown to decrease or abolish HBeAg production.10,11
The polymerase protein functions as a reverse transcriptase as
well as a DNA polymerase. The X protein is a potent transac-
tivator and may play a role in hepatocarcinogenesis.
The replication cycle of HBV begins with the attachment of
the virion to the hepatocyte. Inside the hepatocyte nucleus,
synthesis of the plus strand HBV DNA is completed and the
viral genome is converted into a covalently closed circular
DNA (cccDNA). The cccDNA is the template for the pre-
genomic RNA, which is reverse transcribed into the minus
strand HBV DNA. There are two sources of cccDNA: entry of
new virus particles into the hepatocyte and translocation of
newly synthesized HBV DNA from the hepatocyte cytoplasm.
Most antiviral agents that have been examined so far have
little or no effect on cccDNA.12 This accounts for the rapid
reappearance of serum HBV DNA after cessation of antiviral
therapy.
EPIDEMIOLOGY OF HEPATITIS B
Although persons chronically infected with HBV live in all
parts of the globe, HBV is especially endemic in Asia, the
South Pacific Region, sub-Saharan Africa, in certain indige-
nous population groups residing in the Arctic (Alaska, Green-
land, and Northern Canada), Australia, New Zealand, and
populations in South America and the Mid East.7,13,14 HBV
infection is alsomore prevalent in certain groups in developed
countries, such as immigrants from endemic areas, men who
have sex with men, injecting drug users, and persons with
multiple sex partners.5,15-19 In some parts of the world such as
China and sub-Saharan Africa, HCC associated with HBV is
one of the leading causes of cancer in men.6,7 Table 2 displays
the prevalence of HBV serologicmarkers in population groups
that should be screened for HBV infection and immunized if
seronegative.
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HBV is transmitted by perinatal, percutaneous, and sexual
exposure, as well as by close person-to-person contact pre-
sumably by open cuts and sores, especially among children in
hyperendemic areas.5,15-17 HBV can survive outside the body
for prolonged periods, and carriers who are HBeAg positive
can shed large quantities of viral particles (107-9) on environ-
mental surfaces through open cuts or sores.20,21 The risk of
developing chronic HBV infection after acute exposure ranges
from 90% in newborns of HbeAg-positive mothers to 25% to
30% in infants and children under 5 and less than 10% in
adults.22-26 In addition, immunosuppressed persons are more
likely to develop chronic HBV infection after acute infec-
tion.27,28
Recommendations for Persons Who Should Be Screened for HBV
Infection: The following groups should be screened for HBV
infection: persons born in hyperendemic areas, menwho have
sex with men, injecting drug users, dialysis patients, HIV-
infected individuals, pregnant women, and family members,
household members, and sexual contacts of HBV-infected
persons. (II)
TERMINOLOGY AND NATURAL HISTORY OF CHRONIC
HBV INFECTION
The consensus definition and diagnostic criteria for clinical
terms relating to HBV infection adopted at the National Insti-
tutes of Health (NIH) workshop on Management of Hepatitis
B 2000 are summarized in Table 3.1
The most commonly used definition of the carrier state is
presence of HBsAg in serum for at least 6 months. It is impor-
tant to recognize that occasionally it may take a few more
months for some individuals to clear HBsAg, but HBsAg
should be undetectable 1 year after acute HBV infection.25
During the initial phase of chronic HBV infection, serumHBV
DNA levels are high and HBeAg is present. The majority of
carriers eventually lose HBeAg and develop antibody to
HBeAg (anti-HBe).29-33 In most patients who have undergone
seroconversion from HBeAg to anti-HBe, levels of HBV DNA
decrease below detection by unamplified assays (105 copies/
mL), aminotransferase (ALT) levels normalize, and necroin-
flammation decreases.29,32 However, in some patients, liver
disease persists or relapses after a period of inactivity. Most of
these patients have core promoter or precore variants.
Three serologic patterns of chronic HBV infection have
been identified. In Asia and the Oceania, where at least 50% of
TABLE 1. Quality of Evidence on Which Recommendation is Based
Grade Definition
I Evidence from multiple well-designed randomized controlled
trials each involving a number of participants to be of
sufficient statistical power
II Evidence from at least one large well-designed clinical trial
with or without randomization, from cohort or case-control
analytic studies, or well designed meta-analysis
III Evidence based on clinical experience, descriptive studies, or
reports of expert committees
IV Not rated
NOTE. These definitions of “Quality of Evidence” have been modified by
the Practice Guidelines Committee of the American Society for the Study of
Liver Diseases from Categories developed by the Infectious Disease Society of
America’s Quality Standards.2
TABLE 2. Prevalence of HBV Serologic Markers in Population Groups





Persons born in endemic areas 13 70-85
Men who have sex with men 6 35-80
Injecting drug users 7 60-80
Dialysis patients 3-10 20-80
HIV-infected patients 8-11 89-90
Pregnant women (USA) 0.4-1.5
Family/household and sexual contacts 3-6 30-60
TABLE 3. Glossary of Clinical Terms Used in HBV Infection
Definitions
Chronic hepatitis B
Chronic necroinflammatory disease of the liver caused by persistent
infection with hepatitis B virus. Chronic hepatitis B can be
subdivided into HBeAg-positive and HBeAg-negative chronic
hepatitis B.
Inactive HBsAg carrier state
Persistent HBV infection of the liver without significant, ongoing
necroinflammatory disease.
Resolved hepatitis B
Previous HBV infection without further virologic, biochemical, or
histologic evidence of active virus infection or disease.
Acute exacerbation or flare of hepatitis B
Intermittent elevations of aminotransferase activity to more than 10
times the upper limit of normal and more than twice the baseline
value.
Reactivation of hepatitis B
Reappearance of active necroinflammatory disease of the liver in a
person known to have the inactive HBsAg carrier state or resolved
hepatitis B.
HBeAg clearance
Loss of HBeAg in a person who was previously HBeAg positive.
HBeAg seroconversion
Loss of HBeAg and detection of anti-HBe in a person who was
previously HBeAg positive and anti-HBe negative, associated with
decrease in serum HBV DNA to 105 copies/mL.
HBeAg reversion




1. HBsAg positive 6 months
2. Serum HBV DNA 105 copies/mL
3. Persistent or intermittent elevation in ALT/AST levels
4. Liver biopsy showing chronic hepatitis (necroinflammatory score
4)*
Inactive HBsAg carrier state
1. HBsAg positive 6 months
2. HBeAg negative, anti-HBe positive
3. Serum HBV DNA 105 copies/mL
4. Persistently normal ALT/AST levels
5. Liver biopsy confirms absence of significant hepatitis
(necroinflammatory score 4)*
Resolved hepatitis B
1. Previous known history of acute or chronic hepatitis B or the
presence of anti-HBc  anti-HBs
2. HBsAg negative
3. Undetectable serum HBV DNA†
4. Normal ALT levels
*Optional.
†Very low levels may be detectable using sensitive PCR assays.
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chronic HBV infection is a result of perinatal transmission,
persistence of HBeAg is longer and seroconversion does not
occur inmost persons until later in adulthood (pattern 1).34,35
Among individuals with perinatally acquired HBV infection, a
large percent of HBeAg-positive patients have high serum
HBV DNA but normal ALT levels.34,35 These patients are con-
sidered to be in the “immune tolerant” phase. Many of these
patients develop HBeAg-positive chronic hepatitis B with ele-
vated ALT levels described as pattern 2 in later life.33,36,37 In
sub-Saharan Africa, Alaska, and Mediterranean countries,
transmission of HBV usually occurs from person to person in
childhood, whereas perinatal transmission is less common
(pattern 2).25,38-40 In these populations most children who are
HBeAg positive have elevated ALT levels and seroconversion
to anti-HBe is common near or shortly after the onset of pu-
berty. The third pattern is usually observed in individuals who
acquiredHBV infection during adulthood. This pattern is sim-
ilar to pattern 2 and is most common in developed countries
where sexual transmission is the predominant mode of spread
(pattern 3).15,41 Very little longitudinal data is available on the
latter patients, but liver disease is generally present in patients
with high HBV DNA levels.30,32,42
Among adults in Asia and the Oceania with elevated ALT
levels and carriers of all ages with childhood or adult-acquired
HBV infection, the rate of clearance of HBeAg averages be-
tween 8% and 12% per year.29-33,43 The rate of clearance of
HBeAg is much lower in Asian children (most of whom have
normal ALT levels)34,35 and in immunocompromised sub-
jects.28,44 The largest prospective follow-up study conducted
in Alaska of 1,536 carrier children and adults, followed for 12
years, showed that spontaneous HBeAg clearance occurred in
45% of carriers in 5 years and in 80% after 10 years.43 Simi-
larly, 3- and 5-year HBeAg clearance rates of 50% and 70%
were reported in untreated children with elevated ALT levels
from Taiwan and Italy.36,39 Older age and elevated ALT are
predictive of HBeAg clearance. HBeAg clearance may follow
an exacerbation of hepatitis, manifested by an elevation of
ALT levels.31,33
The majority of carriers who develop HBeAg seroconver-
sion remain HBeAg negative and anti-HBe positive with nor-
mal ALT levels andminimal or no necroinflammation on liver
biopsy. This has been referred to as the “inactive carrier
state.”29,32,33,39,40,43,45 The course and outcome of the inactive
HBsAg carrier state is generally but not invariably benign de-
pending on the duration and severity of the preceding chronic
hepatitis. Because fluctuations in ALT and HBV DNA levels
are common during the course of chronic HBV infection, se-
rial tests should be performed before patients are determined
to be in an inactive carrier state and periodically thereafter. Up
to 20% of carriers in the inactive state can have exacerbations
of hepatitis, as evidenced by elevations of ALT levels to 5 to 10
times the upper limit of normal, with or without seroreversion
to HBeAg.33,37,46,47 Repeated exacerbations or reactivations
can lead to progressive fibrosis.
HBeAg-negative chronic hepatitis B, characterized by HBV
DNA levels detectable by nonamplified assays and continued
necroinflammation in the liver, has been reported in all parts
of the world but is more common in Mediterranean countries
and Asia.48-64 Most patients with HBeAg-negative chronic
hepatitis B harbor HBV variants in the precore or core pro-
moter region.49-56,59,62-67 The most common precore muta-
tion, G1896A, creates a premature stop codon in the precore
region thus abolishing production of HBeAg.67 This variant is
commonly found in association with HBV genotype D, which
is prevalent in the Mediterranean basin and is rarely detected
in association with HBV genotype A, which is prevalent in the
United States andNorth-West Europe.51,68 Themost common
core promoter mutations, A1762T  G1764A, decrease tran-
scription of precore messenger RNA and production of
HBeAg.11 There are also clinical differences between HBeAg-
positive and HBeAg-negative chronic hepatitis B.57 Patients
with HBeAg-negative chronic hepatitis B tend to have lower
serum HBV DNA levels and are more likely to run a fluctuat-
ing course characterized by persistently elevated or fluctuat-
ing ALT levels.57,60,62
Approximately 0.5% of HBsAg carriers will clear HBsAg
yearly; most will develop anti-HBs.43,69,70 However, low levels
of HBV DNA detectable only by polymerase chain reaction
(PCR) assays can be found in up to half of these persons after
disappearance of HBsAg.71 The pathogenic significance of
very low levels of HBV DNA is unknown.
One population-based study of HBsAg carriers found the
incidence of decompensated cirrhosis to be 0.5 per 1,000
years.43 In carriers referred to clinical centers, the reported
incidence of cirrhosis is as high as 2% to 3% per year possibly
because of underlying chronic hepatitis.61,72-74 Prognostic fac-
tors for the development of cirrhosis include HBeAg positiv-
ity, older age, and elevated ALT levels.72,73,75 For patients with
compensated cirrhosis, the survival is 84% at 5 years and 68%
at 10 years.75,76 In carriers with decompensated cirrhosis,
5-year survival is only 14%.76,77 In patients with cirrhosis, risk
factors for decompensation include presence of HBeAg and
failure to respond to interferon.77,78 Patients with compen-
sated cirrhosis who were HBeAg-negative had significantly
better 5-year survival (97%) than those who were HBeAg-
positive (72%).76 Clearance of HBeAg, whether spontaneous
or after antiviral therapy, reduces the risk of hepatic decom-
pensation and improves survival.72,74,76-81
Risk factors for HCC in patients with chronic HBV infection
include male gender, family history of HCC, older age, pres-
ence of cirrhosis, and coinfection with hepatitis C virus
(HCV).6,7,43,77,82 It is important to note that, although HCC is
more common in persons with cirrhosis, 30% to 50% of HCC
associated with HBV occurs in the absence of cirrhosis.7
Clearance of HBsAg decreases the risk of hepatic decompen-
sation and probably HCC,69,83 but HCC can occur in long-
term carriers who have cleared HBsAg.43,70,84
Coinfection with HCV or human immunodeficiency virus
(HIV) is commonly seen in injecting drug users.5 Coinfection
with HIV is also seen in men who have sex with men. Persons
who are chronically coinfected with HBV and HCV may have
more rapid progression of liver disease85 and a higher risk of
developing HCC than carriers with HBV infection only.7 In-
dividuals with HBV and HIV coinfection tend to have higher
levels of HBV DNA, lower rates of spontaneous HBeAg sero-
conversion,28,44 and more severe liver disease.86
Hepatitis D virus (HDV) is a satellite virus, which is depen-
dent on HBV for the production of envelope proteins.87 HBV/
HDV coinfection most commonly occurs in the Mediterra-
nean area and parts of South America. The availability of HBV
vaccines and public health education on prevention of trans-
mission of HBV infection has led to a significant decline in the
prevalence of HDV infection in the past decade.88,89 HDV in-
fection can occur in two forms. The first form is caused by the
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coinfection of HBV and HDV; this usually results in a more
severe acute hepatitis with a higher mortality rate than is seen
with acute hepatitis B alone,87,90 but rarely results in chronic
infection. A second form is a result of a superinfection of HDV
in an HBV carrier. HDV superinfection can manifest as a se-
vere “acute” hepatitis in previously asymptomatic HBV carri-
ers or exacerbations of underlying chronic hepatitis B. Unlike
coinfection, HDV superinfection in HBV carriers almost al-
ways results in chronic infection with both viruses. Although
persons with chronic HBV/HDV infection can exhibit a wide
spectrum of liver pathology, a higher proportion develops
cirrhosis, hepatic decompensation, and HCC compared with
those with chronic HBV infection alone.91,92
EVALUATION AND MANAGEMENT OF PATIENTS WITH
CHRONIC HBV INFECTION
Initial Evaluation
The initial evaluation of patients with chronic HBV infec-
tion should include a thorough history and physical examina-
tion, with special emphasis on risk factors for coinfection,
alcohol use, and family history of HBV infection and liver
cancer. Laboratory tests should include assessment of liver
disease, markers of HBV replication, and tests for coinfection
with HCV, HDV, and HIV in those at risk (Table 4). Vaccina-
tion for hepatitis A should be administered as per Centers for
Disease Control recommendations to persons with chronic
hepatitis B.93 Prevaccination screening for antibody to hepa-
titis A (total or IgG) should be considered if the prevalence of
infection in the population is likely to be greater than 33%.93
Recommendations for Vaccinating Persons With Chronic HBV In-
fection Against Hepatitis A: All persons with chronic hepatitis B
not immune to hepatitis A should receive 2 doses of hepatitis
A vaccine 6 to 18 months apart.
The appropriate HBV DNA assay to use for initial evalua-
tion of patients with chronic HBV infection has not been de-
termined. An arbitrary value of105 copies/mLwas chosen as
a diagnostic criterion for chronic hepatitis B at a recent NIH
conference.1 However, there are problems with this defini-
tion. First, assays for HBV DNA quantification are not well
standardized (Table 5).94-96 Second, some patients with
chronic hepatitis B have fluctuating HBV DNA levels that may
at times fall below 105 copies/mL. Third, the threshold HBV
DNA level that is associated with progressive liver disease is
unknown. Quantitative amplification assays can detect HBV
DNA levels as low as 102 copies/mL but the results of these
assays have to be interpreted with caution because of the un-
certain clinical significance of low HBV DNA levels. Based on
our current knowledge and definition of chronic hepatitis B,
unamplified assays with detection limits of 105 to 106 cop-
ies/mL are adequate for the initial evaluation of patients with
chronic HBV infection.
The purpose of a liver biopsy is to assess the degree of liver
damage and to rule out other causes of liver disease. An inter-
national panel of experts recommended that the histologic
diagnosis of chronic hepatitis should include the etiology,
grade of necroinflammatory activity, and stage/extent of fibro-
sis.97 Several numerical scoring systems have been established
to permit statistical comparisons of necroinflammatory activ-
ity and fibrosis.98-100 Histologic findings may help in predict-
ing prognosis.101 However, it must be recognized that liver
histology can improve significantly in patients who have sus-
tained response to antiviral therapy or spontaneous HBeAg
seroconversion. Liver histology also can worsen rapidly in
patients who have recurrent exacerbations or reactivations of
hepatitis. Liver biopsies can be used for immunohistochemi-
cal staining for HBsAg and hepatitis B core antigen.
Follow-up of Patients not Considered for Treatment
HBeAg-Positive Patients With High Serum HBV DNA but Normal
ALT Levels. These patients should be monitored at 3- to
6-month intervals (Table 4). In general, liver biopsy is not
necessary unless treatment is contemplated. More frequent
monitoring should be performed when ALT levels become
elevated. Exacerbations in liver disease have been reported in
up to 40% of patients prior to spontaneous HBeAg clear-
ance.31,33,37,47 Patients who remain HBeAg positive with HBV
DNA levels greater than 105 copies/mL after a 3- to 6-month
period of elevated ALT levels should be considered for liver
biopsy and antiviral treatment.
Recommendations for Monitoring Patients With Chronic HBV In-
fection: (1) HBeAg-positive patients with elevated ALT levels
may be observed for 3 to 6 months for spontaneous serocon-
version from HBeAg to anti-HBe prior to initiation of treat-
ment (III).
(2) Patients who meet the criteria for chronic hepatitis B
(serumHBVDNA105 copies/mL and persistent or intermit-
tent elevation in aminotransferase levels) should be evaluated
further with a liver biopsy (III).
(3) Patients in the inactive HBsAg carrier state should be
monitored with periodic liver biochemistries as liver disease
may become active even after many years of quiescence (III).
COUNSELING AND PREVENTION OF HEPATITIS B
Patients with chronic HBV infection should be counseled
regarding lifestyle modifications and prevention of transmis-
sion. There are no specific dietary measures that have been
shown to have any effect on the progression of chronic hepa-
titis B. However, heavy use of alcohol (40 g/d) has been
associated with higher ALT levels102,103 and development of
cirrhosis.104 In addition, the development of cirrhosis and
HCC occurs at a younger age in heavy drinkers with chronic
hepatitis B.105,106
TABLE 4. Evaluation of Patients With Chronic HBV Infection
Initial evaluation
History and physical examination
Laboratory tests to assess liver disease—complete blood counts with
platelets, hepatic panel, and prothrombin time
Tests for HBV replication—HBeAg/anti-HBe, HBV DNA
Tests to rule out other causes of liver disease—anti-HCV, anti-HDV
Tests to screen for HCC—AFP and, in high risk patients, ultrasound
Liver biopsy to grade and stage liver disease—for patients who meet
criteria for chronic hepatitis
Suggested follow-up for patients not considered for treatment
HBeAg-positive chronic hepatitis with HBV DNA  105 copies/mL and
normal ALT
ALT every 3-6 months
If ALT 1-2  ULN, recheck ALT every 1-3 months
If ALT 2  ULN for 3-6 months and patient is HBeAg positive, HBV
DNA 105 copies/mL, consider liver biopsy and treatment
Consider screening for HCC in relevant population
Inactive HBsAg carrier state
ALT every 6-12 months
If ALT 1-2  ULN, check serum HBV DNA level and exclude other
causes of liver disease
Consider screening for HCC in relevant population
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Carriers of HBV should be counseled as to the risk of trans-
mission to others. Counseling should include precautions to
prevent sexual transmission, perinatal transmission, and risk
of inadvertent transmission via environmental contamination
from a blood spill. Householdmembers are at increased risk of
HBV infection and therefore should be vaccinated if they test
negative for HBV serologicmarkers.5 Screening should be per-
formed by testing for HBsAg and anti-HBs. A positive result
for antibody to hepatitis B core antibody does not differentiate
between recovered and chronic infection. In addition, false-
positive test results are not uncommon in persons with iso-
lated antibodies to hepatitis B core antigen.107,108 Vaccination
of sexual partners has been shown to be effective in preventing
sexual transmission of HBV.5 Steady sexual partners should
be tested and vaccinated against hepatitis B if found to be
seronegative. For casual sex partners or steady partners who
have not been tested or have not completed the full immuni-
zation series, barrier protectionmethods should be employed.
HBsAg-positive women who are pregnant should be coun-
seled to make sure they inform their providers so hepatitis B
immune globulin (HBIG) and hepatitis B vaccine can be ad-
ministered to their newborn immediately after delivery.5 In
addition, they should be informed that their infants need to
complete the recommended vaccination schedule and have
follow-up testing for HBV seromarkers at 1 year of age. HBIG
and concurrent hepatitis B vaccine have been shown to be
95% efficacious in the prevention of perinatal transmission of
HBV.16,109 Carriers should be advised to cover open cuts and
scratches and clean up blood spills with bleach, because HBV
can survive on environmental surfaces for at least 1 week.20 It
should be noted that carriers with high HBV DNA levels are
more likely to be infectious, as evidenced by transmission
from maternal carriers to infants.110 Occupational trans-
mission of HBV has also been shown to occur in rare in-
stances.111,112 For HBV carriers who are health care workers,
the Centers for Disease Control recommends that those who
are HBeAg-positive should not perform invasive procedures
without prior counseling and advice from an expert review
panel under what circumstances, if any, they should be al-
lowed to perform these procedures.113 These circumstances
would include notifying prospective patients of their HBV
status prior to procedures.
Recommendations for Prevention of Transmission of Hepatitis B
From IndividualsWith Chronic HBV Infection: (1)Carriers should
be counseled regarding prevention of transmission of HBV. (I)
(2) Sexual and household contacts of carriers should be
tested for HBV (HBsAg and anti-HBs) and if negative receive
hepatitis B vaccination. (II)
(3) Newborns of HBV-infected mothers should receive
HBIG and hepatitis B vaccine at delivery and complete the
recommended vaccination series. (I)
(4) Persons who remain at risk for HBV infection such as
infants of HBsAg-positive mothers, health care workers, and
dialysis patients should be tested for response to vaccination.
Infants of carrier mothers should be tested 3 to 9 months, and
health care workers 1 to 6 months after vaccination, and dial-
ysis patients should be tested annually. (I)
(5) Abstinence or only limited use of alcohol is recom-
mended in hepatitis B carriers. (III)
Periodic Screening for HCC
In longitudinal prospective studies, carriers of HBV have
clearly been shown to be at increased risk of developing
HCC.6,7,39 HCCmay have a long asymptomatic stage lasting 2
years or longer.114 In the majority of patients, the cancer be-
gins as a single tumor that is often encapsulated. The doubling
time of HCC has been estimated to range from 2 to 12 months
with a median of 4 months.115-117 There is considerable evi-
dence that HCC can be detected early when persons with
chronic HBV or HCV infection receive periodic screening.
Four population-based screening studies using alpha-fetopro-
tein (AFP) have been published in HBV carriers, three involv-
ing periodic screening and one reporting a one-time mass
screening.118-121 Using AFP as a screening method, small
HCC, defined as tumors with a diameter of less than 5 cm,
were found in 37% to 59% of persons who had HCC. In clinic-
based periodic screening studies involving persons with HBV
utilizing both AFP and ultrasound (US) small tumors were
found in 57% and 83% of persons respectively with
HCC.122,123 Effective treatment modalities for small HCC
have resulted in successful ablation of tumor and reports of
long-term tumor-free survival.124-129
Patients with small HCC detected by AFP screening and
surgically resected who have survived for more than 5 to 10
years have been reported in two population-based stud-
ies.118,119 Duration of tumor-free survival of greater than 5
years would mean that lead time bias is unlikely to be a factor.
One of these studies utilizing only AFP compared survival in
screened patients with nonscreened historical controls from
the same population and showed significant improvement in










Branched DNA (Bayer) 10 L 2.1 7  105 7  105-5  109 A,B,C,D,E,F 6-15%
Hybrid capture 30 L 0.5 1.4  105 2  105-1  109 A,B,C,D 10-15%
(Digene) 1 mL 0.02 5  103 5  103-3  106
Liquid hybridization
(Abbott)
100 L 1.6 4.5  105
[8  106]†
5  105-1  1010 Detects genotype D
better than A
12-22%
PCR-Amplicor 50 L 0.001 4  102 4  102-1  107 (A),B,C,D,E 14-44%
(Roche) Cobas: 105
Taqman: 1010
Molecular Beacons 10-50 L — 50 50 - 1  109 A-F 5-10%
Adapted from Zuezem S.25
*1 pg HBV DNA  283,000 copies (3  105 viral genome equivalents).
†Corrected limit of detection.
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5- and 10-year survival rates.119 Other uncontrolled clinic-
based studies have reported long-term survivors who had ei-
ther surgery or percutaneous ethanol injection after detection
of small HCC.126 Although there is strong evidence that long-
term survival can occur in some patients with small HCC that
are treated surgically, no randomized trials of carriers under-
going periodic screening compared with those not screened
have been reported. In addition, it is important to note that a
high false-positive rate of AFP in HBV carriers with chronic
hepatitis or cirrhosis may result in expensive evaluations such
as radiographic procedures and liver biopsy.
Based on the risk factors discussed in the Natural History
section, while it would be easy to identify groups of carriers to
prioritize for screening (i.e., men 45 years of age, carriers
with cirrhosis or a family history of HCC), carriers of any age,
even asymptomatic persons with normal ALT levels and min-
imal or absent liver disease, can develop HCC. The study from
Alaska showed a distinct survival advantage for younger pa-
tients detected with HCC, most of whom did not have cirrho-
sis.119 However, most HCC develops after decades of chronic
HBV infection. Thus, the optimal age to initiate periodic
screening is not known.
Several prospective screening studies in HBsAg carriers us-
ing laboratory and radiographic tests have been per-
formed.119-123,130-134 Of the laboratory tests that have been
used, AFP has been studied most extensively. The sensitivity
of AFP testing depends on the cutoff level employed. The
normal level of AFP is less than 8 to 12 ng/mL. If a level of 20
ng/mL is used, the sensitivity for small HCC ranges from 50%
to 75%. The specificity of AFP is above 90% in studies that
include not only individuals with chronic hepatitis or cirrho-
sis but also carriers in the inactive state. The negative predic-
tive value is greater than 99%.119, 122 However, the positive
predictive value is low, ranging from 9% to 30%. AFP levels
that rise in a step-like manner strongly suggest the presence of
HCC, and persons with persistent mild elevation of AFP
(200 ng/mL) are at a higher risk of HCC than those with a
single increased value.119 Other markers that have been
shown to be elevated in small HCC in cross-sectional studies
include des--carboxy prothrombin (DCP), serum--glu-
tamyl transferase isoenzyme II, and alpha-L-fucosidase.135-140
Only DCP has been studied in a prospective manner. Several
studies have shown that, while DCP can be elevated in small
HCC, the sensitivity of DCP is less than AFP.135-137 However,
two recent studies using a more sensitive assay suggest that
DCP and AFP are complimentary and result in a higher sen-
sitivity than either test alone.141,142 DCP assays are not com-
mercially available in the United States and have not been
evaluated as a screening tool.
US is the only radiographic test that has been prospectively
studied as an imaging tool for HCC surveillance. Extracting
data regarding US from clinic-based studies, the sensitivity for
small HCC ranged from 68% to 87% and false-positive rate
from 28% to 82%.122,123,133,134,143 Regenerating nodules, seen
in patients with cirrhosis, are the most common reason for
false-positive results. US is considerably more expensive than
AFP, and, in most developed countries, requires a radiologist.
In addition, US is operator dependent and sensitivity of US in
detecting small HCC varies depending on the skill of the ul-
trasound technologist and the radiologist. In addition, large
body habitus canmake visualization of the liver more difficult
and detection of small tumors in cirrhotic livers can be a
challenge. However, US is more sensitive for small HCC than
AFP. The combination of AFP and US appears to be superior
to either alone but only one randomized trial has been re-
ported, and the number of cases detected and the follow-up
period (36 months) was too short to determine if any differ-
ence in early detection exists.122 No randomized trials exam-
ining the frequency of HCC surveillance in HBV carriers (or
persons with other liver conditions at risk for HCC) have been
reported. However, when reviewing the results of 6 clinic-
based studies utilizing AFP and US, involving 140 to 1,069
patients with cirrhosis due to HBV or HCV, screening every 6
months appears superior to yearly screening in the detection
of small HCC.122,123,130-133 There appeared to be no difference
between screening every 3 or 6 months.
Few cost effectiveness studies on surveillance for HCC in
patients with chronic HBV infection have been reported. One
clinic-based study from Hong Kong, which has a socialized
health care system, using AFP and US for all patients, and
computerized tomography for those with AFP levels greater
than 20 ng/mL, showed that the cost per tumor detected was
$1,667.144 In this study using AFP for initial screening 61% of
HCCwere discovered at a resectable stage. In other studies the
cost per tumor detected ranged from $11,800 to $25,000.121,145
In the cohort of carriers from the Alaska study,146 cost per
quality of adjusted life year saved ranged from $10,000 to
$15,000, well below the widely accepted limit of $50,000 per
quality of adjusted life year gained. However, prospective
studies on the cost effectiveness and impact of surveillance for
HCC on survival need to be conducted before definitive rec-
ommendations on HCC surveillance can be made.
In conclusion, the data available on which to support rec-
ommendations for HCC surveillance suggest the following:
(1) Periodic testing can detect HCC at a resectable stage in
greater than 50% of the instances. (2) Some carriers can ex-
perience long-term survival after resection of small HCC, and
one study comparing screened cases to historical controls
showed a significant survival advantage. (3) Screening with
AFP alone has been shown to detect HCC early in some car-
riers from endemic areas where there is a high risk of perinatal
or early childhood infection, and one population study in
predominantly noncirrhotic carriers demonstrated 10-year
tumor free survival in 27%. (4) US, while more costly, appears
to be more sensitive than AFP and the combination of US and
AFPmay be best. (5) The sensitivity of AFP is less than US but
the negative predictive value is high, 99% in low-risk carriers,
suggesting that AFP could be used as an initial screening test
in low-risk individuals without cirrhosis.120,122,143 (6) While
carriers at higher risk can be identified, all carriers could ben-
efit from periodic testing with AFP. The age to initiate screen-
ing for low-risk carriers and the frequency of testing is not
known. Evidence to date suggests that carriers with low risk of
HCC could be screened with AFP and those at high risk with
AFP and US. (7) The age at which screening for HCC should
begin is unknown. (8) The optimal frequency for surveillance
appears to be every 6 months. The exact risk of HCC in non-
endemic populations, such as adult-infected white carriers
living in developed countries, has not been determined and
the role of periodic screening in this population is not known.
Recommendations for HCC Screening: (1) HBV carriers with
high risks for HCC such as men over 45 years, persons with
cirrhosis, and persons with a family history of HCC, should be
screened periodically with both AFP and US. (III)
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While there are insufficient data to recommend routine
screening in low-risk patients with chronic HBV infection,
periodic screening for HCC with AFP in carriers from en-
demic areas should be considered. (III)
TREATMENT OF CHRONIC HEPATITIS B
The aims of treatment of chronic hepatitis B are to achieve
sustained suppression of HBV replication and remission of
liver disease. The end points used to assess treatment response
include normalization in serum ALT level, undetectable se-
rumHBVDNA by an unamplified assay, loss of HBeAgwith or
without detection of anti-HBe, and improvement in liver his-
tology. Inconsistencies in the definition of response, lack of
standardization of HBV DNA assays, and heterogeneity in pa-
tient populations make it difficult to compare response rates
in clinical trials of treatment of chronic hepatitis B. At the
recent NIH workshop on Management of Hepatitis B, it was
proposed that responses to antiviral therapy of chronic hepa-
titis B be categorized as biochemical (BR), virologic (VR), or
histologic (HR), and as on-therapy or sustained off-therapy
(Table 6).1 Currently, two therapeutic agents have been ap-
proved by the FDA for the treatment of chronic hepatitis B.
Interferon
Interferons (IFNs) have antiviral, antiproliferative, and im-
munomodulatory effects. Interferon alfa (IFN-) has been
shown to be effective in suppressing HBV replication and in
inducing remission of liver disease. However, its efficacy is
limited to a small percentage of highly selected patients.
Efficacy in Various Categories of Patients.
1. HBeAg-positive chronic hepatitis B with the following:
a. Persistent or intermittent elevation in ALT. This pat-
tern is seen in “typical” chronic hepatitis B patients.
A meta-analysis of 15 randomized controlled trials
involving 837 adult patients found that a signifi-
cantly higher percentage of IFN-–treated patients
had a virologic response compared with untreated
controls (Table 7).147 High pretreatment ALT and
low serum HBV DNA levels are the most important
predictors of a response to IFN- therapy.148-150
b. Normal ALT. This pattern is usually seen in children
or young adults with perinatally acquired HBV in-
fection. Virologic response to IFN- therapy is ob-
served in less than 10% of these patients.150-153
c. Asian patients. Trials in Asian patients with HBeAg-
positive chronic hepatitis B found that while the re-
sponse in patients with normal ALT was poor,153 the
response in patients with elevated ALT was similar
to that in white patients.150
d. Children. The efficacy of IFN- is similar to that in
adults. Among children with elevated ALT, HBeAg
clearance has been reported in 30% of those who re-
ceived IFN- compared with 10% of controls.154-156
However, less than 10% of children with normal ALT
levels, who received IFN- cleared HBeAg.151,152
One meta-analysis of 240 children found that IFN-
treatment increased HBV DNA clearance (odds ratio
2.2), HBeAg clearance (odds ratio 2.2), and ALT nor-
malization (odds ratio 2.3) compared with untreated
controls.157 Adverse events were similar to that in
adults.
2. HBeAg-negative chronic hepatitis B
HBeAg loss or seroconversion cannot be used as an end
point to assess response in these patients. Therefore,
response is usually defined as undetectable serum HBV
DNA by unamplified assays and normalization of ALT
level. Analyses of the results of trials of IFN- in HBeAg-
negative chronic hepatitis B are complicated by the het-
erogeneity not just of the disease, but also the virus and
study designs. Results of four randomized controlled
trials involving a total of 86 IFN-–treated patients and
84 controls showed that the end-of-treatment response
ranged from 38% to 90% in treated patients compared
with only 0% to 37% of controls. The 12-month sus-
tained response rates varied from 10% to 47% (average
24%) among the treated patients and 0% in the con-
trols.158-161 Neither pretreatment factors nor IFN-
dose was predictive of response but longer duration of
treatment (12 vs. 6 months) was associated with a
doubling of the sustained response rates.1,162,163 A ma-
jor problem with IFN- treatment of HBeAg-negative
chronic hepatitis B is relapse, approximately half of the
responders relapse when therapy is discontinued, and
relapses can occur up to 5 years post-therapy.164 Never-
theless, sustained response can be achieved in 15% to
25% of patients and long-term follow-up showed that
15% to 30% of sustained responders cleared HBsAg.1,164
3. Nonresponders to IFN treatment
Most studies found that retreatment of IFN- nonre-
TABLE 6. Definition of Response to Antiviral Therapy
of Chronic Hepatitis B
Category of response
Biochemical (BR) Decrease in serum ALT to within the normal
range
Virologic (VR) Decrease in serum HBV DNA to undetectable
levels in unamplified assays (105 copies/
mL), and loss of HBeAg in patients who
were initially HBeAg positive
Histologic (HR) Decrease in histology activity index by at least
2 points compared with pretreatment liver
biopsy
Complete (CR) Fulfill criteria of biochemical and virologic
response and loss of HBsAg
Time of assessment
On-therapy During therapy
Maintained Persist throughout the course of treatment
End-of-treatment At the end of a defined course of therapy
Off-therapy After discontinuation of therapy
Sustained (SR-6) 6 months after discontinuation of therapy
Sustained (SR-12) 12 months after discontinuation of therapy
TABLE 7. Antiviral Response to Interferon and Lamivudine Therapy
in Patients With HBeAg-Positive Chronic Hepatitis B
Interferon Lamivudine
12-24
Weeks Controls 52 Weeks Controls
Loss of serum HBV DNA 37% 17%
Loss of HBeAg 33% 12% 17%-32% 6%-11%
HBeAg seroconversion Difference of 18% 16%-18% 4%-6%
Loss of HBsAg 7.8% 1.8% 1% 0
Normalization in ALT Difference of 23% 41%-72% 7%-24%
Histologic improvement 49%-56% 23%-25%
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sponders with IFN- alone was associated with a very
low rate of response. However, a recent trial reported an
HBeAg clearance rate of 33% among patients retreated
with IFN- versus 10% in untreated controls.165 Unfor-
tunately, this trial included patients who were previ-
ously treated with suboptimal doses of IFN- and may
have overestimated the benefits of IFN- retreatment.
4. HBV DNA–positive clinical cirrhosis
Approximately 20% to 40% of patients with HBeAg-
positive chronic hepatitis B develop a flare in their ALT
values during IFN- treatment. The flare is believed to
be a reflection of IFN-induced immune-mediated lysis
of infected hepatocytes and is considered to be a predic-
tor of response. In patients with cirrhosis, the flare may
precipitate hepatic decompensation. Two studies on
IFN- in patients with Child’s class B or C cirrhosis
reported no benefit. In addition, significant side effects
due to bacterial infection and exacerbation of liver dis-
ease occurred even with low doses of IFN- (3 MU
every other day).166,167 However, IFN- is safe and may
be effective in patients with compensated cirrhosis. In
clinical trials of patients with HBeAg-positive chronic
hepatitis, up to 60% of patients included had histologic
cirrhosis, and less than 1% of patients who received
standard doses of IFN- developed hepatic decompen-
sation.149,150
Dose Regimen. IFN- is administered as subcutaneous injec-
tions. The recommended dose for adults is 5 MU daily or 10
MU thrice weekly and for children 6 MU/m2 thrice weekly
with a maximum of 10 MU. The recommended duration of
treatment for patients with HBeAg positive chronic hepatitis B
is 16 to 24 weeks. There are very little data on longer courses
of treatment in patients with HBeAg-positive chronic hepatitis
B.168-170 One study found that the response was similar in
patients who received 12 versus 24 weeks of IFN-.169 An-
other study reported that among patients who have not
cleared HBeAg after 16 weeks of IFN-, those randomized to
continue treatment until week 32 had significantly higher
rates of HBeAg clearance compared with those who stopped
treatment.170 Current data suggest that patients with HBeAg-
negative chronic hepatitis B should be treated for at least 12
months but it is not clear if longer duration of treatment will
increase the rate of sustained response.
Prednisone Priming. The rationale for administering a taper-
ing course of steroids prior to antiviral therapy (prednisone
priming) is that recovery of immune function following ste-
roid withdrawal may be beneficial particularly if this is timed
with the initiation of IFN- therapy. A meta-analysis of 7
randomized trials of IFN- with or without prednisone prim-
ing in 376 patients with HBeAg-positive chronic hepatitis
failed to show a significant benefit of steroid pretreatment.171
However, a subsequent study of 200 European patients re-
ported that patients who received prednisone priming had a
significantly higher rate of HBeAg seroconversion.172 Al-
though a small subset of patients may benefit from prednisone
priming, there is a risk of fatal exacerbations in patients with
underlying cirrhosis. Therefore, prednisone priming is not
recommended as a primary treatment of chronic hepatitis B.
Adverse Events. IFN- therapy is associated with many ad-
verse effects. Of these, flu-like symptoms, fatigue, leucopenia,
and depression are the most common. Most patients develop
tolerance to the flu-like symptoms after the first week, but
fatigue, anorexia, hair loss, and mood swings including anxi-
ety, irritability, and depression may persist throughout the
course of treatment and for a few weeks after discontinuation
of therapy. IFN- may also unmask or exacerbate underlying
autoimmune disorders. An analysis of 9 randomized con-
trolled trials with 552 patients showed that 35% of the pa-
tients treated with IFN- required dose reduction and 5%
required premature cessation of treatment.173
Durability of Response and Long-TermOutcome of IFN-–Treated
Patients. IFN-–induced HBeAg clearance has been reported
to be durable in 80% to 90% of patients after a follow-up
period of 4 to 8 years.80,81,174-176 However, HBV DNA re-
mained detectable in the serum from most of these patients
when tested by PCR assays. Five studies in Europe and the
United States reported that delayed clearance of HBsAg oc-
curred in 12% to 65% of patients within 5 years of HBeAg loss,
but delayed HBsAg clearance was not observed in 2 studies on
Chinese patients.78-81,174,175,177 Sustained virologic response is
usually accompanied by a decrease in necroinflammation of
the liver but residual hepatic injury is frequently present.178
Several studies reported that the 5-year cumulative rates of
HBeAg clearance were similar in treated patients and controls,
but IFN-–treated patients were more likely to have normal
ALT levels and to clear HBsAg.79,179 These findings suggest
that the main role of IFN- may be to reduce the duration of
active liver disease by hastening viral clearance. Data on long-
term clinical benefits of IFN- treatment are limited because
chronic hepatitis B is an insidious disease, and adverse out-
comes such as progression to cirrhosis, hepatic decompensa-
tion, or HCC may not be evident until decades later. In addi-
tion, patients initially randomized to the control group
frequently receive treatment after completion of the trial.
There has been only one report comparing the outcome of
treated patients and controls. An 8-year follow-up of 101male
patients who participated in a controlled trial of IFN- ther-
apy in Taiwan found that treated patients had a lower inci-
dence of HCC (1.5% vs. 12%, P  .04) and a higher survival
rate (98% vs. 57%, P  .02).80 IFN- has not been shown to
decrease the incidence of HCC in European or North Ameri-
can patients probably because of the low rate of HCC in un-
treated patients.79,81 Studies comparing the outcome of re-
sponders versus nonresponders found that patients who
cleared HBeAg had better overall survival and survival free of
hepatic decompensation.78,80,81
Data on long-term outcome of patients treated for HBeAg-
negative chronic hepatitis B are very limited. It has been esti-
mated that up to 20% of long-term responders cleared HBsAg
after 5 years of follow-up.1,164 In addition, long-term respond-
ers appear to have reduced risks of HCC and liver-related
deaths.164
Lamivudine (Epivir-HBV, 3TC)
Lamivudine is the () enantiomer of 2	-3	 dideoxy-3	-thia-
cytidine. Incorporation of the active triphosphate (3TC-TP)
into growing DNA chains results in premature chain termina-
tion thereby inhibiting HBV DNA synthesis.
Efficacy in Various Categories of Adult Patients.
1. HBeAg-positive chronic hepatitis B with the following:
a. Persistent or intermittent elevation in ALT. Three clin-
ical trials involving a total of 731 treatment naı̈ve
patients who received lamivudine for 1 year reported
that HBeAg seroconversion (defined as the loss of
HBeAg, detection of anti-HBe, and loss of serum
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HBV DNA based on non-PCR assays) occurred in
16% to 18% of patients compared with 4% to 6% of
untreated controls180-182 (Table 7). Histologic im-
provement defined as a reduction in necroinflamma-
tory score greater than 2 points was observed in 49%
to 56% treated patients and in 23% to 25% of con-
trols. Follow-up reports of the multicenter Asian
study showed that HBeAg seroconversion rates in-
creased with the duration of treatment from 17% at 1
year to 27%, 33%, and 47% at 2, 3, and 4 years,
respectively.183-185 Whether the incremental HBeAg
seroconversion can be attributed to the additional
years of lamivudine treatment is unclear because
most of the patients randomized to placebo in the
second year were transferred to open-label lamivu-
dine treatment.
Pretreatment ALT has been found to be the most
important predictor of response.186 Pooled data from
406 patients who received lamivudine 100 mg daily
for 1 year showed that HBeAg seroconversion oc-
curred in 2%, 9%, 21%, and 47% of patients with
pretreatment ALT levels within normal, 1-2 times
normal, 2-5 times normal, and more than 5 times
normal.187 The corresponding figures for 196 pa-
tients in the placebo group were 0%, 5%, 11%, and
14%, respectively.
b. Normal ALT levels. HBeAg seroconversion rate after
1 year of treatment is less than 10% in patients with
pretreatment ALT levels less than 2 times nor-
mal.186,187
c. Asian patients. Asians respond similarly to lamivu-
dine as white patients.
d. Children. Experience with lamivudine in children is
limited. One controlled trial involved 286 children,
aged 2 to 17 years, with ALT levels greater than 1.3
times normal. The childrenwere randomized in a 2:1
ratio to lamivudine (3 mg/kg/d up to 100 mg/d) or
placebo for 52 weeks. A preliminary report of this
trial showed that a significantly higher proportion
of treated children developed HBeAg seroconver-
sion compared with placebo controls, 23% versus
13%.187a As with adults, the HBeAg seroconversion
rate was higher among children with pretreatment
ALT levels greater than 2 times normal (34% vs.
16%). The adverse event profile of the two groups
was similar. These data indicate that lamivudine is
safe and effective in children but the benefit must be
carefully balanced against the risk of selecting drug
resistant mutants. In this trial, lamivudine-resistant
HBV mutants were detected in 18% of treated chil-
dren.
2. HBeAg-negative chronic hepatitis B
Lamivudine has been shown to benefit patients with
HBeAg-negative chronic hepatitis B.188-193 In one study,
virologic and biochemical response was achieved in 34
of 54 (63%) patients who received 24 weeks of lamivu-
dine therapy versus 3 of 53 (6%) patients on placebo
(P  .001). Of the 54 patients who completed 1 year of
lamivudine treatment, serum HBV DNA was undetect-
able by bDNA assay in 65% and by PCR assay in 39% of
patients, and histologic improvement was observed in
60% of patients.188 Other studies have reported similar
1-year response rates of 70%.189,191,193 However, the
vast majority (90%) of patients relapsed when treat-
ment was stopped.194
3. Nonresponders to IFN- treatment
In a multicenter trial on IFN- nonresponders, 238 pa-
tients were randomized to receive lamivudine mono-
therapy for 52 weeks, lamivudine for 8 weeks followed
by a combination of lamivudine and IFN- for another
16 weeks, or no treatment. Patients who received lami-
vudine monotherapy had the highest HBeAg serocon-
version rate, 18% compared with 12% and 13%, respec-
tively, in the other groups (not significant).195 These
data suggest that patients who failed IFN- treatment
have a similar response to lamivudine as treatment-na-
ive patients, and retreatment with combination of
IFN- and lamivudine did not confer any added benefit
compared with retreatment with lamivudine mono-
therapy.
4. HBsAg-positive clinical cirrhosis
Studies of lamivudine in patients with decompensated
cirrhosis showed that lamivudine treatment is well tol-
erated and results in clinical improvement in many pa-
tients,196-199 but the optimal timing for initiation of
treatment and the subset of patients that are most likely
to benefit remain to be determined. In one study of 35
patients (10with Child-Pugh class C and 25with Child-
Pugh class B), improvement in liver disease defined as a
decrease in Child-Pugh score of greater than 2 was ob-
served in 22 of 23 patients who received a minimum of
6 months treatment.197 However, 7 patients had pro-
gressive liver disease necessitating liver transplant and
an additional 5 died during the first 6 months. A major
concern with early treatment is the selection of resistant
mutants. In the study mentioned above,197 3 patients
developed breakthrough infection. Although all 3 re-
mained clinically stable, more data are needed to deter-
mine the long-term outcome of cirrhotic patients who
develop lamivudine resistance, their risks of recurrent
hepatitis B, and the efficacy of HBIG in the prevention of
recurrent hepatitis B after liver transplantation.
Adverse Events. In general, lamivudine is very well tolerated.
Various adverse events including amild (2- to 3-fold) increase
in ALT level have been reported in patients receiving lamivu-
dine, but these events occurred in the same frequency among
the controls.180-182
Durability of Response. There are very limited data on the
durability of HBeAg seroconversion after lamivudine is dis-
continued. Preliminary data from an ongoing observational
study of responders in phase II or III lamivudine trials re-
ported that 34 of 42 (81%) patients with HBeAg seroconver-
sion had durable response after a median follow-up of 21
months (range, 0-30 months). ALT levels were normal in 28
(65%) patients. In addition, 9 (21%) patients had HBsAg se-
roconversion.200 However, two studies from Asia reported
lower rates of durable response, 38% to 73%.185, 201 In the
study fromKorea, 34 patients hadHBeAg seroconversion after
a mean duration of treatment of 9.3  3.0 months.201 Post-
treatment, the cumulative relapse rates at 1 and 2 years were
38% and 49%. Most, 12 of 16, relapses occurred within the
first 12months after cessation of treatment. Multivariate anal-
ysis found that duration of additional lamivudine therapy af-
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ter HBeAg seroconversion and pretreatment serum HBV DNA
levels were independent predictors for post-treatment relapse.
Lamivudine Resistance. Selection of lamivudine-resistant
mutants is the main concern with lamivudine treatment. The
most common mutation affects the YMDD motif of the
HBV DNA polymerase (methionine to valine or isoleucine
M204V/I, formerly M552V/I).202,203 This mutation is fre-
quently accompanied by a leucine to methionine substitution
in an upstream region (L180M formerly L528M). Lamivudine
resistance is usually manifested as breakthrough infection de-
fined as reappearance of HBV DNA in serum using an unam-
plified assay on two or more occasions after its initial disap-
pearance. However, breakthrough infection also can be a
result of noncompliance. Genotypic resistance can be de-
tected in 14% to 32% after 1 year of treatment.180-182 In the
Asian study, genotypic resistance increased from 14% in year
1 to 38%, 49%, and 66% after 2, 3, and 4 years of treatment,
respectively.183-185 The clinical course of patients with lami-
vudine resistant mutants is variable and the long-term out-
come remains to be determined. In some patients, emergence
of lamivudine-resistant mutants may be accompanied by
acute exacerbations of liver disease and rarely hepatic decom-
pensation.204-206 However, most patients who continue treat-
ment have lower serum HBV DNA and ALT levels compared
with their pretreatment levels. The continued benefit may be
related to the suppressive effect of lamivudine on residual
wild-type virus and the impaired replication capacity of the
mutants.207,208 In addition, HBeAg seroconversion has been
reported in approximately 25% of the patients who continued
treatment after the detection of lamivudine-resistant mu-
tants.183,204
The rates of lamivudine resistance in patients treated for
HBeAg-negative chronic hepatitis B appear to be more vari-
able (0% to 27% at 1 year and 10% to 56% at 2 years).188-190,192
More studies are needed to determine the rate of lamivudine
resistance in patients treated for HBeAg-negative chronic hep-
atitis B and the clinical outcome of those who develop break-
through infection.
Dose Regimen. The recommended dose for adults with nor-
mal renal function (creatinine clearance50mL/min) and no
HIV coinfection is 100 mg daily orally. The recommended
dose for children is 3 mg/kg/d with a maximum dose of 100
mg/d. Dose reduction is necessary for patients with renal in-
sufficiency. Patients with HIV coinfection should be treated
with twice daily 150-mg doses in addition to other anti-retro-
viral therapies.
The end point of treatment for HBeAg-positive patients is
HBeAg seroconversion. In general, lamivudine should be ad-
ministered for 1 year as a shorter duration of therapy is asso-
ciated with lower rates of HBeAg seroconversion.180-182,209,210
Treatment may be discontinued in patients who have com-
pleted 1 year of treatment and have persistent HBeAg serocon-
version (HBeAg loss, anti-HBe detection, and serum HBV
DNA undetectable by non-PCR assays on more than one oc-
casion determined 2-3 months apart). Durability of response
after cessation of treatment is expected to be 70% to 80%.
Whether lamivudine can be discontinued in patients who
have completed 1 year of treatment and have sustained HBeAg
loss but no detectable anti-HBe remains to be determined.
Based on data from the Korean study,201 it is not advisable to
discontinue treatment before 1 year in patients who have early
HBeAg seroconversion.
Treatment may be continued in patients who have not
achieved HBeAg seroconversion and have no evidence of
breakthrough infection as HBeAg seroconversion may occur
with continued treatment.183 However, treatment beyond 1
year has not been adequately investigated and the benefits of
continued treatment must be balanced against the risks of
resistant mutants.
Treatment may be continued in patients who have break-
through infection caused by lamivudine-resistant mutants as
long as benefit to the patient (based on clinical assessment,
ALT, and HBV DNA levels) is maintained. Patients with wors-
ening liver disease caused by lamivudine-resistant mutants
should be referred for clinical trials on potential “rescue” ther-
apy with other nucleoside/nucleotide analogues such as ad-
efovir dipivoxil or entecavir.
Acute exacerbations of hepatitis with or without hepatic
decompensation may occur after discontinuation of lamivu-
dine therapy. Exacerbations may occur even in patients who
have developed HBeAg seroconversion and may occur up to 1
year (median 4 months) after cessation of treatment.211 Thus,
all patients should be closelymonitored for at least 1 year after
treatment is discontinued. Reinstitution of lamivudine treat-
ment is usually effective in controlling the exacerbations in
patients who have not experienced breakthrough infection
and may result in subsequent HBeAg seroconversion,211 but
the benefits of retreatment are usually tranisent in patients
with breakthrough infection as resistant mutants are quickly
selected when lamivudine is resumed.192
The end point of treatment for HBeAg-negative chronic
hepatitis B is unknown. Post-treatment relapse can occur even
in patients with undetectable serum HBV DNA by PCR assay.
Because of the high rate of relapse in patients who responded
after 1 year of treatment, longer duration of treatment may be
needed. However, the criteria for discontinuation of treatment
has not been determined and the clinical significance of lami-
vudine resistant mutants in patients with core promoter/pre-
core HBV variants remain unclear.
Other Therapies
Famciclovir. Famciclovir is the oral prodrug of penciclovir.
Clinical studies showed that famciclovir is well tolerated and
effective in suppressing HBV replication but its antiviral effect
is less potent than that of lamivudine. A phase III clinical trial
of 417 patients with HBeAg-positive chronic hepatitis B found
a higher rate of HBeAg seroconversion compared with con-
trols, 9% versus 3%.212 Resistance to famciclovir including
L180M (L528M) mutation has been reported.213 In view of
the low efficacy, need for thrice daily administration, and po-
tential for cross-resistance with lamivudine, it is unlikely that
famciclovir will have a major role in the treatment of chronic
hepatitis B.
Adefovir Dipivoxil. Adefovir dipivoxil is the prodrug of ad-
efovir. Phase I and II clinical trials showed that adefovir de-
creased serum HBV DNA levels by 2 to 4 log.214 Adefovir in
high doses is associated with nephrotoxicity. Phase III clinical
trials are ongoing to determine the safety and efficacy of lower
doses of adefovir. In vitro and preliminary clinical data
showed that adefovir is effective in suppressing the replication
of lamivudine-resistant HBV mutants.215,216
Other Antiviral Agents. Other antiviral agents that have
shown promise in clinical trials include emtricitabine
(FTC)217 and entecavir.218 In vitro studies showed that ente-
cavir is effective against lamivudine-resistant HBV mutants219
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but there are no published data on its in vivo efficacy in pa-
tients with breakthrough infection due to these mutants.
Thymosin. Thymic-derived peptides can stimulate T-cell
function. Clinical trials have shown that thymosin is well tol-
erated but data on efficacy are conflicting.220-223 Thus, more
studies are needed before thymosin can be recommended for
treatment of chronic hepatitis B.
Combination Therapies
Combination therapies may have additive or synergistic an-
tiviral effects and reduce or delay resistance. Combination
therapies have been proven to be more effective in the treat-
ment of chronic HCV and HIV infections. The potential dis-
advantages of combination therapies include added costs, in-
creased toxicities, and drug interactions.
IFN- and Lamivudine. Combination therapy of IFN- and
lamivudine has been evaluated in two studies. In one study,
226 treatment-naı̈ve patients were randomized to receive
lamivudine monotherapy for 52 weeks or IFN- alone for 16
weeks or lamivudine for 8 weeks followed by lamivudine and
IFN- for 16 weeks. At week 52, the rates of HBeAg serocon-
version were 18%, 19%, and 29% in the groups that received
lamivudinemonotherapy, IFN-monotherapy, and combina-
tion therapy, respectively (not significant).182 These data in-
dicate that a 1-year course of lamivudine has similar antiviral
efficacy to a 16-week course of IFN- in treatment-naı̈ve pa-
tients, and the combination of lamivudine and IFN- does not
seem to have any added benefit. Similar results were reported
in the other study on IFN- nonresponders.195 However prob-
lems in the design of these two studies including sample size,
shorter duration of lamivudine therapy (24 vs. 52 weeks) in
the group that received combination therapy, and timing of
the second biopsy (28weeks post-treatment vs. on-treatment)
prevent a definitive conclusion concerning the efficacy of
combination therapy of IFN- and lamivudine. Studies using
other regimens are ongoing. Until further data are available,
combination therapy of IFN- and lamivudine is not recom-
mended.
Lamivudine and Famciclovir. In vitro and in vivo studies in
woodchucks showed that lamivudine and penciclovir have
additive or synergistic antiviral effects. A pilot study found
that a short course of combination therapy of lamivudine and
famciclovir have added antiviral efficacy.224 Whether these
effects will translate into higher rates of sustained antiviral
response or lower rates of resistant mutants remain to be de-
termined.
Coinfection With HBV and HDV
The primary endpoint of treatment is the suppression of
HDV replication, which is usually accompanied by normaliza-
tion of ALT level and necroinflammatory activity on liver bi-
opsy. In most countries, the only approved treatment of
chronic hepatitis D is IFN-. Data on the efficacy of IFN- in
chronic hepatitis D are limited. One trial on 61 patients com-
paring IFN- in doses of 3 to 5 MU/m2 3 times a week for 12
months versus placebo found that there was no difference in
sustained virologic response between treated patients and
controls, and only 1 patient had sustained biochemical re-
sponse.225 Another trial on 42 patients found that patients
who received high dose (9 MU 3 times a week) IFN- had
higher rates of virologic and biochemical as well as histologic
response.226 Although most patients had virologic relapse,
improvement in liver histology was maintained 10 years
post-treatment among the patients who received high-dose
IFN-.227
Lamivudine has been evaluated in a small number of pa-
tients and found to be ineffective in inhibiting HDV replica-
tion.228
Based on available data, high-dose IFN- (9 MU 3 times a
week) for 1 year appears to have long-term beneficial effects in
patients with chronic hepatitis D. Because of the rarity of
hepatitis D, patients with chronic hepatitis D should be re-
ferred to specialized centers for treatment.
Recommendations for the Treatment of Chronic Hepatitis B: Who
to treat and what treatment to use (Table 8): Current therapy of
chronic hepatitis B has limited long-term efficacy. Thus, care-
ful balance of patient’s age, severity of liver disease, likelihood
of response, and potential adverse events and complications is
needed before treatment is initiated. Except for patients with
decompensated cirrhosis, either IFN- or lamivudine may be
used as initial therapy. The advantages of IFN- include finite
duration of treatment and lack of resistant mutants. The dis-
advantages of IFN- are the costs and side effects. Lamivudine
is more economical (if given for 1 year only) and well toler-
ated but the durability of response and the long-term clinical
significance of the resistant mutants are uncertain.
1. Patients with HBeAg-positive chronic hepatitis B
a. ALT greater than 2 times normal or moderate/severe
hepatitis on biopsy. These patients should be consid-
ered for treatment. Treatment may result in viro-
logic, biochemical, and histologic response (I) and
also appear to improve clinical outcome (II). Treat-
ment may be initiated with lamivudine or IFN- as
the 2 treatments have similar efficacy.
b. ALT persistently normal or minimally elevated (2
times normal). These patients should not be initiated
on treatment unless there is significant necroinflam-
mation on liver biopsy (II).
c. Children with elevated ALT greater than 2 times nor-
mal. These patients should be considered for treat-
TABLE 8. Recommendations for Treatment of Chronic Hepatitis B
HBeAg
HBV
DNA* ALT Treatment Strategy
  2 normal Low efficacy for both IFN- and
lamivudine treatment.
Observe patient, consider treatment
when ALT becomes elevated.
  2 normal IFN- or lamivudine therapy. In IFN-
nonresponders and patients with
contraindications to IFN-,
lamivudine is preferred.
  2 normal IFN- or lamivudine. Long-term
treatment required.
  2 normal No treatment required.
/  Cirrhosis Compensated: IFN- (close monitoring
required) or lamivudine
Decompensated: Lamivudine treatment.
Optimal timing of therapy unknown.
Liver transplantation.
/  Cirrhosis Compensated: Observe.
Decompensated: Liver transplantation.
*HBV DNA 105 copies/mL. This value is arbitrarily chosen and may be
lower for patients with HBeAg-negative chronic hepatitis B and those with
decompensated cirrhosis.
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ment (II). Both IFN- and lamivudine are approved
treatments for children with chronic hepatitis B.
2. Patients with HBeAg-negative chronic hepatitis B (se-
rumHBVDNA105 copies/mL, elevated ALT2 times
normal or moderate/severe hepatitis on biopsy) should
be considered for treatment (II). Treatment may be ini-
tiated with lamivudine or IFN- (II).
3. Patients who failed to respond to prior IFN- therapy
may be retreated with lamivudine if they fulfill the cri-
teria listed above (II).
4. Patients with decompensated cirrhosis may be consid-
ered for lamivudine treatment (III). Treatment should
be coordinated with transplant centers. IFN- should
not be used in patients with decompensated cirrhosis
(II).
5. In patients with inactive HBsAg carrier state antiviral
treatment is not indicated.
Dose Regimens.
1. IFN- is administered as subcutaneous injections.
a. The recommended IFN- dose for adults is 5 MU daily
or 10 MU thrice weekly.
b. The recommended IFN- dose for children is 6 MU/m2
thrice weekly with a maximum of 10 MU.
c. The recommended treatment duration for HBeAg-posi-
tive chronic hepatitis B is 16 weeks.
d. The recommended treatment duration for HBeAg-neg-
ative chronic hepatitis B is 12 months.
2. Lamivudine is administered orally.
a. The recommended lamivudine dose for adults with nor-
mal renal function and no HIV coinfection is 100 mg
daily.
b. The recommended lamivudine dose for children is 3
mg/kg/d with a maximum of 100 mg/d.
c. The recommended treatment duration for HBeAg-posi-
tive chronic hepatitis B is 1 year. Treatment may be
continued in patients who have not developed
HBeAg seroconversion but treatment beyond 1 year
should balance the benefits against the risks of resis-
tant mutants. Treatment may be continued in pa-
tients who have breakthrough infection due to lami-
vudine-resistant mutants as long as benefit to the
patient (based on clinical assessment, ALT, and HBV
DNA level) is maintained.
d. The recommended treatment duration for HBeAg neg-
ative chronic hepatitis B is longer than 1 year but the
optimal duration has not been established.
APPENDIX
The Practice Guidelines Committee Members are as follows:
Henry C. Bodenheimer, Jr.,MD (Chair); David Eric Bernstein, MD;
Gary L. Davis, MD; James Everhart, MD; Stuart C. Gordon, MD; F.
Blaine Hollinger, MD; Donald M. Jensen, MD; Maureen Jonas, MD;
Jacob Korula, MD; Timothy M. McCashland, MD; Jan M. Novak,
MD; Melissa Palmer, MD; Rajender Reddy, MD; Eve A. Roberts, MD;
James R. Spivey, MD; Thomas Shaw-Stiffel, MD.
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